ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2003

Colchicine As a Therapeutic Option in Periodic Fever Aphtous  Stomatitis, Pharingitis Syndrome.   and Cervical Adenitis (PFAPA)

Yonatan butbul Aviel1, Sameh Tatour2, Ruth Gershoni3 and Riva Brik4, 1Pediatric Rheumatology, Rambam Medical Center, Haifa, Israel, 2Pediatric Unit B, Rambam Medical Center, Israel, 3Genetics Unit, Rambam, Israel, 4Pediatric Unit B, Rambam Medical center

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Fever and pediatric rheumatology

  • Tweet
  • Email
  • Print
Session Information

Session Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: PFAPA syndrome is episodic  disease characterized by periodic episodes of high fever, aphthous stomatitis, pharyngitis, and cervical adenitis, so far no therapy was shown to be effective in preventing the attacks.

The aim of our study was to evaluate the efficacy of colchicine in reducing  attacks of  PFAPA.

Methods:

We carried a randomized control study among patients diagnosed with PFAPA in the pediatric Rheumatology clinic- Rambam Medical center, Israel.

The patients were randomized into two groups followed for 6 months. In months

1-3 both groups were followed without preventive therapy; In months 4-6, group1 continued to be followed in the same manner, patients in group2 received colchicine for three months in a standard dose. During the study patients and physician recorded all PFAPA episodes, in a log book. DNA analysis for the common FMF mutation was done for all patients.

Results:

14 patients 5.8±1.9 years old were evaluated(8 in group1, 6 in group2).

The number of episodes in the first 3 months were 3.5±1.3 in group1 and 4.9±2.45 in group2 (p-0.187), the number of episodes in group2 under colchicine therapy were 1.7±1 compared to 4.9±2.4 in the period without therapy(p-0.01).

Seven patients were found to be carrier of one FMF mutation;(4 in group2 and 3 in group1). Patients with PFAPA who carry one mutation for FMF responded  to colchicine therapy (6.1±2 episodes before and 2±1.4 after therapy p-0.03).

Conclusion: : Colchicine therapy might be effective in increasing intervals between  episodes of PFAPA. Larger studies are needed to confirm these findings.


Disclosure:

Y. butbul Aviel,
None;

S. Tatour,
None;

R. Gershoni,
None;

R. Brik,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/colchicine-as-a-therapeutic-option-in-periodic-fever-aphtous-stomatitis-pharingitis-syndrome-and-cervical-adenitis-pfapa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies